Journal of Cancer Research and Clinical Oncology最新文献

{"title":"The status and determinants of demoralization in patients with colorectal cancer: a cross-sectional study in China.","authors":"Dan Zhou, Fanfan Shi, Jie Yang, Lili Jiang, Luo Yang, Jin Wen","doi":"10.1007/s00432-025-06206-w","DOIUrl":"10.1007/s00432-025-06206-w","url":null,"abstract":"<p><strong>Background: </strong>To investigate the occurrence and severity of demoralization syndrome (DS) in colorectal cancer (CRC) patients in China, and explore its influencing factors, so as to provide evidence for the formulation of psychological care strategies for colorectal cancer patients.</p><p><strong>Methods: </strong>This study was a cross-sectional design. A questionnaire was formulated to investigate the demographic, disease characteristics and treatment information, demoralization syndrome, social support, anxiety and depression of patients, who treated in Colorectal Cancer Center of West China Hospital of Sichuan University from May to July 2023. t test, Wilcoxon rank sum test, Chi-square test or Fisher exact probability method were used for univariate analysis, and binary logistic regression analysis was used to explore the factors affecting demoralization syndrome.</p><p><strong>Results: </strong>445 colorectal cancer patients participated in this study, and the median score of demoralization syndrome was 10 (5-14), showing moderate demoralization syndrome. Univariate analysis showed that gender, tumor metastasis, social support, anxiety and depression might related to the severity of demoralization syndrome. Binary logistic regression showed, patients without tumor metastasis had a lower risk of developing moderate-to-severe demoralization syndrome compared with patients with tumor metastasis (OR = 0.522, 95%CI 0.319 ~ 0.848). The higher the anxiety and depression score, the higher the risk of moderate to severe demoralization syndrome (OR = 1.490, 95%CI 1.349 ~ 1.657, and OR = 1.167, 95%CI 1.073 ~ 1.272), P < 0.001.</p><p><strong>Conclusions: </strong>It is necessary to consider the disease characteristics of colorectal cancer patients and the impact of treatment on patients to develop psychological nursing strategies comprehensively.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"156"},"PeriodicalIF":2.7,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12053192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA PET/CT for prostate cancer diagnosis: current applications and future directions.","authors":"Zhengang Shen, Zeng Li, Yunlong Li, Xiaodi Tang, Jiayi Lu, Li Chen, Zhu Zhong Cheng, Hong Liao, Shukui Zhou","doi":"10.1007/s00432-025-06184-z","DOIUrl":"10.1007/s00432-025-06184-z","url":null,"abstract":"<p><p>Prostate cancer (PCa) requires improved diagnostic strategies beyond conventional imaging. This review aimed to evaluate the role of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) in diagnosing advanced PCa. The review analyzed the diagnostic performance of PSMA PET/CT in various clinical contexts, including locoregional staging, extracapsular extension (ECE), seminal vesicle invasion (SVI), pelvic lymph node metastases, distant metastases, and biochemical recurrence (BCR). Further, challenges such as PSMA-negative tumors, need for standardized protocols, and potential of emerging imaging targets (neurotensin receptor 1 and fibroblast activation proteins) were reviewed. The role of artificial intelligence (AI) and advancements in tracer development were explored. PSMA PET/CT demonstrated exceptional specificity for locoregional staging, ECE, and SVI while reducing unnecessary biopsies and optimizing biopsy strategies. The diagnostic accuracy for pelvic lymph node metastases was higher with PSMA PET/CT than with traditional methods, although sensitivity for micrometastasis detection remained challenging. For distant metastases, PSMA PET/CT outperformed bone scintigraphy (BS) and conventional imaging, particularly in identifying bone and atypical lesions. In BCR cases, PSMA PET/CT reliably detected recurrent lesions at low prostate-specific antigen levels, significantly influencing treatment strategies. The review findings indicate that PSMA PET/CT is a superior diagnostic tool for PCa due to its high specificity and accuracy. Despite limitations such as PSMA-negative tumors and sensitivity challenges, advancements in AI, novel imaging targets, and affordable tracer development hold promise for broader clinical adoption. This review underscores the transformative potential of PSMA PET/CT in PCa diagnosis and management, advocating for ongoing research and protocol standardization.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"155"},"PeriodicalIF":2.7,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RGS14 promotes the progression of hepatocellular carcinoma by activating the cAMP/PKA/CREB signaling pathway.","authors":"Xiangnan Liang, Bin Xu, Qiuxiang Wang, Kai Gong, Chun Han, Binwen Sun, Kexin Ma, Liming Wang","doi":"10.1007/s00432-025-06212-y","DOIUrl":"10.1007/s00432-025-06212-y","url":null,"abstract":"<p><strong>Background: </strong>G protein-coupled receptors (GPCRs) mediate the intracellular signals that drive tumor development. Regulator of G protein signaling 14 (RGS14), a key negative regulator of GPCR signaling, influences liver injury, fat metabolism, and inflammation. However, the role of RGS14 in hepatocellular carcinoma (HCC) progression and its underlying mechanisms remain unclear.</p><p><strong>Methods: </strong>In this study, we compared three pairs of HCC tissues and matched portal vein tumor thrombus (PVTT) samples using 4D-FastDIA proteomics to identify differentially expressed proteins. The clinical significance of RGS14 expression was further evaluated in HCC patient cohorts. Stable RGS14-overexpressing/knockdown cell models were established for functional assays (CCK-8, colony formation, Transwell, and wound healing assays). Additionally, tumor proliferation was evaluated through in vivo studies using a subcutaneous xenograft mouse model. RNA sequencing and western blot analysis were subsequently applied to validate the potential downstream signaling pathways.</p><p><strong>Results: </strong>The results revealed that RGS14 was overexpressed in HCC tissues, which was correlated with adverse clinical outcomes. We also confirmed that RGS14 increased the proliferation, colony formation, migration, and invasion and promoted the epithelial‒mesenchymal transition (EMT) of HCC cells both in vitro and in vivo. Mechanistically, RGS14 elevated intracellular cAMP levels, activating the PKA/CREB axis to drive HCC progression.</p><p><strong>Conclusion: </strong>Our findings suggest that RGS14 plays a critical oncogenic role in HCC by regulating cAMP/PKA/CREB pathway activation, underscoring its potential as both a prognostic marker and therapeutic target for HCC patients.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"153"},"PeriodicalIF":2.7,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased expression of DNAJC7 promotes the progression of hepatocellular carcinoma by influencing the cell cycle and immune microenvironment.","authors":"Jiaxing Chen, Zhizhao Yang, Yongqiang Cui, Zhilei Zhao, Dongfeng Deng, Zhihao Fu, Xiao Zhang","doi":"10.1007/s00432-025-06202-0","DOIUrl":"10.1007/s00432-025-06202-0","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the leading cause of cancer-related mortality worldwide owing to the lack of effective and early diagnostic tools and therapeutic approaches. DNAJC7, a member of the DnaJ heat shock family, is crucial in protein folding and stability; however, its specific functions and mechanisms in HCC remain unclear.</p><p><strong>Objective: </strong>This study aimed to explore the role of DNAJC7 in HCC progression and evaluate its potential clinical significance as a prognostic marker.</p><p><strong>Methods: </strong>Public databases (TCGA, ICGC, GEO, and TIMER) were used to assess DNAJC7 expression, correlations with clinical parameters, and related signaling pathways. Proliferation, migration, invasion, and cell cycle assays were performed to evaluate the function of DNAJC7 in HCC. Immune infiltration and associations with checkpoint proteins were analyzed using TIMER, and a Gene Set Enrichment Analysis (GSEA) was used to explore enriched pathways.</p><p><strong>Results: </strong>DNAJC7 expression was higher in HCC tissues than in adjacent normal tissues and was associated with advanced malignancy and poor prognosis, including a lower overall survival, progression-free survival, and disease-free survival. DNAJC7 knockdown resulted in reduced malignant behavior of HCC cells, leading to S-phase cell cycle arrest. Increased DNAJC7 expression was associated with immune cell infiltration and the presence of immunological checkpoint molecules, including CTLA4 and PD-1. GSEA highlighted the activation of key pathways, including WNT signaling and cell cycle regulation.</p><p><strong>Conclusion: </strong>DNAJC7 regulates tumor cell proliferation, migration, invasion, and immune evasion by acting as an oncogene in HCC. It can serve as a diagnostic and prognostic biomarker and potential treatment target for HCC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"154"},"PeriodicalIF":2.7,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12045834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical pathological characteristics and prognostic analysis of renal primitive neuroectodermal tumours: a multicentre retrospective study of 16 cases in Northwest China.","authors":"Jing Du, Bo Guo, Jiayan Liu, Zhenzhen Li, Xilian Zhao, Mingyu Shao, Fan Yang","doi":"10.1007/s00432-025-06210-0","DOIUrl":"https://doi.org/10.1007/s00432-025-06210-0","url":null,"abstract":"<p><strong>Objective: </strong>Renal primitive neuroectodermal tumours (rPNETs) are extremely rare and highly aggressive malignancy, posing significant diagnostic and therapeutic challenges. This study aims to describe the clinicopathological characteristics, treatment strategies, and survival outcomes of 16 cases of rPNET from multiple centers in Northwest China, and to explore potential prognostic factors.</p><p><strong>Methods: </strong>A multicenter retrospective study was conducted, including 16 patients diagnosed with rPNET across five hospitals in Northwest China. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) were employed to assess the expression of molecular markers, including P53, BCL-2, Ki-67, and EWSR1 gene rearrangements. Survival analysis was performed using the Kaplan-Meier method, and prognostic factors were evaluated using univariate and multivariate Cox regression models.</p><p><strong>Results: </strong>The median age of the patients was 39 years, with a median Ki-67 proliferation index of 50%. P53 mutations were detected in 87.0% of cases, and BCL-2 positive expression was observed in 56.25% of cases. The median overall survival (OS) was 14 months. Univariate analysis revealed that age, tumor stage, BCL-2 expression, and Ki-67 index were significantly associated with OS. Multivariate analysis identified high Ki-67 expression (HR = 1.100, 95% CI: 1.030-1.174, p = 0.004) and negative BCL-2 expression (HR = 0.151, 95% CI: 0.026-0.888, p = 0.037) as independent risk factors for poor prognosis. Kaplan-Meier survival curves demonstrated that the median OS was significantly shorter in patients with high Ki-67 expression (12 months) compared to those with low Ki-67 expression (20 months) (Log-rank test, P < 0.01). Similarly, the median OS was significantly shorter in the BCL-2 negative group (10 months) compared to the BCL-2 positive group (24 months) (Log-rank test, P < 0.05).</p><p><strong>Conclusion: </strong>The absence of rosette structures does not exclude the diagnosis of rPNET. BCL-2 and Ki-67 expression are significant prognostic factors, with high Ki-67 expression and negative BCL-2 expression associated with worse outcomes. These findings highlight the importance of molecular markers in risk stratification and treatment planning for rPNET.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"151"},"PeriodicalIF":2.7,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12034590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and antimicrobial therapy of bloodstream infections in tumour patients with special reference to antibiotic stewardship.","authors":"Jiri Rejthar, Maximilian Desole, Andrea Stroux, Pierre Kremer, Lars Geerdts, Anna Kopf, Madlen Löbel, Joanna Lasocka, Heidrun Peltroche-Llacsahuanga, Martin Schmidt-Hieber","doi":"10.1007/s00432-025-06204-y","DOIUrl":"https://doi.org/10.1007/s00432-025-06204-y","url":null,"abstract":"<p><p>Bloodstream infections (BSI) are among the most frequent infections in tumour patients. We analysed 123 tumour patients (105 retrospective, 18 prospective) with BSI. The most common underlying tumour diseases were acute leukaemia/myelodysplastic syndrome (40%), followed by lymphomas (25%) and multiple myeloma (20%). BSI were more frequently caused by Gram-negative than Gram-positive bacteria (53% vs. 40%), including Escherichia coli (33%), coagulase-negative Staphylococcus spp. (14%), and Pseudomonas aeruginosa (10%). The median time to fever resolution was 3 days (range 1-30 days). Neither pathogen type, initial antibiotic treatment, nor key patient characteristics significantly affected fever resolution time. Non-susceptibility of the pathogen to empirical antibiotic treatment was linked to prolonged fever resolution (HR 0.53, 95%-CI 0.28-1.0, p = 0.04). The severity of neutropenia on admission had a significant impact on 60-day survival (HR 2.95, 95%-CI 1.10-7.93, p = 0.03). In contrast, such an effect on survival was not observed by the non-susceptibility of the pathogen to primary empirical antibiotic treatment (HR 2.12, 95%-CI 0.71-6.30, p = 0.18). Non-adherence or questionable adherence to antibiotic stewardship (ABS) recommendations (n = 42, 34%) correlated with delayed fever resolution (median 3 days vs. 4 days; p = 0.04) and was more frequent in retrospectively than in prospectively recorded patients (38% vs. 11%, p = 0.03). Gram-negative bacteria still predominate as BSI agents in tumour patients. Prospective evaluation of anti-infective management may enhance adherence to ABS recommendations.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"152"},"PeriodicalIF":2.7,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12034589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line pazopanib in patients with metastatic epithelioid hemangioendothelioma: a retrospective single-center analysis.","authors":"Anton Burkhard-Meier, Vera Valerie Rechenauer, Vindi Jurinovic, Markus Albertsmeier, Michael Hoberger, Hans Roland Dürr, Alexander Klein, Thomas Knösel, Wolfgang G Kunz, Andreas Mock, Ada Pusztai, Michael Völkl, Michael von Bergwelt-Baildon, Lars H Lindner, Dorit Di Gioia, Luc M Berclaz","doi":"10.1007/s00432-025-06208-8","DOIUrl":"https://doi.org/10.1007/s00432-025-06208-8","url":null,"abstract":"<p><strong>Purpose: </strong>Epithelioid hemangioendothelioma (EHE) represents an ultra-rare, translocated vascular sarcoma with a heterogeneous course of disease. The optimal systemic treatment for patients with advanced EHE remains unclear. We sought to evaluate the value of pazopanib (PAZ) as a first-line treatment in metastatic EHE.</p><p><strong>Methods: </strong>Thirteen patients with metastatic EHE and PAZ as a first-line treatment at our institution between 2012 und 2023 were reviewed and analyzed with regard to clinical outcomes.</p><p><strong>Results: </strong>At a median follow-up of 51.4 months, the median progression-free survival (PFS) and overall survival (OS) were 35.1 and 53.8 months, respectively. In patients with documented prior tumor progression (n = 10), the median PFS and OS were 12.6 and 105 months, respectively. In patients with serosal effusion/ systemic symptoms (n = 4), the median PFS and OS were 6.1 and 10.3 months. The clinical benefit rate of the overall cohort was 62% with no complete or partial responses. Two of four patients experienced a reduction of symptoms (pain and ascites reduction/hemoptysis, respectively) under treatment with PAZ. Toxicity was mainly gastrointestinal and manageable with dose reductions. Permanent treatment interruption due to toxicity was necessary in one patient.</p><p><strong>Conclusion: </strong>This is the first study to systematically report survival outcomes for PAZ as a first-line treatment in patients with metastatic EHE. PAZ is active and safe in patients with metastatic EHE and may be considered as an alternative to sirolimus for specific patient subgroups. RECIST criteria should be questioned for evaluation of treatment response in EHE.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"150"},"PeriodicalIF":2.7,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12033179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers.","authors":"Siyer Roohani, Jolina Handtke, Kamal Hummedah, Markus Albertsmeier, Dimosthenis Andreou, Leonidas Apostolidis, Marinela Augustin, Sebastian Bauer, Moritz Billner, Florian Bösch, Christoph K W Deinzer, Niklas Deventer, Anna Duprée, Franziska Eckert, Lars Engel, Katja Fechner, Hagen Fritzsche, Verena Gaidzik, Saeed Ghani, Robert Grützmann, Wiebke K Guder, Rainer Hamacher, Judith S Hecker, Anne Hendricks, Axel Hillmann, Philipp Houben, Georg Hübner, Philipp Ivanyi, Christina Jentsch, Maren Jordan, Peter Kappl, Moritz Kaths, Torsten Kessler, Johanna Kirchberg, Carolin Knebel, Robert Krempien, Burkhard Lehner, Ulrich Lenze, Lars H Lindner, Alisa Martina Lörsch, Nadia Maguire, Sophie Müller, Pompiliu Piso, Vlatko Potkrajcic, Peter Reichardt, Stephan Richter, Simone Schewe, Lars M Schiffmann, Felicitas Scholten, Jana Käthe Striefler, Matthias Schwarzbach, Katharina Seidensaal, Sabine Semrau, Joanna Szkandera, Christoph J Szuszies, Beate Timmermann, Armin Tuchscherer, Armin Wiegering, Moritz T Winkelmann, David Kaul, Jens Jakob","doi":"10.1007/s00432-025-06193-y","DOIUrl":"https://doi.org/10.1007/s00432-025-06193-y","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"149"},"PeriodicalIF":2.7,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12021966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical implications of miR-195 in cancer: mechanisms, potential applications, and therapeutic strategies.","authors":"Shuli Xu, Lan He, Yan Chen, Ting Lin, Le Tang, Yonghui Wu, Yingchun He, Xiaofeng Sun","doi":"10.1007/s00432-025-06195-w","DOIUrl":"10.1007/s00432-025-06195-w","url":null,"abstract":"<p><p>This review explores the dual role of miR-195 in cancer, acting as both a tumor suppressor and, in specific contexts, a tumor promoter. It highlights its molecular mechanisms, focusing on key signaling pathways such as Wnt-1/β-catenin, VEGF/VEGFR, and PI3K/AKT/mTOR, as well as its involvement in competitive gene regulation. The clinical potential of miR-195 in cancer screening, diagnosis, prognosis, and therapy is examined, particularly its ability to enhance therapeutic efficacy and reduce recurrence risk when combined with chemotherapy or immunotherapy. Despite these promising aspects, challenges such as precise regulation, efficient delivery systems, and clinical translation remain. Future research should prioritize advancing miR-195's integration into personalized medicine, immunotherapy, and novel delivery technologies, aiming to establish it as a reliable biomarker and therapeutic target for improved cancer care.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"148"},"PeriodicalIF":2.7,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12014848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management strategies for primary lung carcinosarcoma: a case study and comprehensive literature review.","authors":"Zhonglian Wang, Ying Zeng, Hongting Jiang, Cha Luo, Fei Zhang, Xiaofeng Zhu, Qiaofen Fu","doi":"10.1007/s00432-025-06203-z","DOIUrl":"https://doi.org/10.1007/s00432-025-06203-z","url":null,"abstract":"<p><strong>Background: </strong>Primary lung carcinosarcoma, characterized by the presence of both carcinoma and sarcoma components, is a rare soft tissue malignancy. Its pathogenesis remains incompletely elucidated, and it exhibits significant resistance to conventional therapeutic interventions, resulting in a dismal prognosis. Consequently, there is currently no established standard treatment protocol for lung carcinosarcoma, leading most clinicians to draw upon their experiences with other tumor types when formulating treatment strategies.</p><p><strong>Case description: </strong>A 56-year-old non-smoking male presented with a progressively enlarging mass in the right cervical region, The diagnosis of lung carcinosarcoma was definitively confirmed through CT-guided biopsy. First-line immunotherapy combined with targeted therapy was ineffective; second-line chemotherapy was effective, chest CT revealed the disappearance of enlarged lymph nodes in the retrosternal area and a significant reduction of pulmonary lesions, but showed signs of brain metastasis. the patient passed away at home on June 27th, 2023 due to sudden onset dyspnea accompanied by loss of consciousness.</p><p><strong>Literature review: </strong>A comprehensive literature search for lung carcinosarcoma was conducted across four databases, including PubMed/MEDLINE, Web of Science, Cochrane Library, and Embase, covering the period from 1968 to 2023. A total of 48 patients were included for analysis. Further survival analysis revealed a median survival time of 18 months; adjuvant therapy following surgery significantly improved survival compared to surgery alone and other treatment modalities.</p><p><strong>Conclusion: </strong>Lung carcinosarcoma is an exceptionally rare malignant neoplasm of the lung, and definitive treatment protocols remain elusive. The most effective strategy to enhance prognosis may still entail complete surgical resection of the lesions in conjunction with adjuvant therapy.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 4","pages":"147"},"PeriodicalIF":2.7,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12014741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}